Seroprevalence of delta hepatitis in patients with chronic hepatitis B and its clinical impact in Khuzestan Province, Southwest Iran

Hepatitis Monthly

Volumn 9, Issue 4, 2009, Pages 287-292

  Hajiani, Eskandar ^a   Hashemi, Seyed Jalal ^a   Jalali, Fariba ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic hepatitis; HBV; HDV; Iran; Khuzestan

Indexed keywords

HEPATITIS ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS DELTA VIRUS ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DELTA AGENT HEPATITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; IRAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; SEROPREVALENCE; SEX DIFFERENCE; UNIVERSITY HOSPITAL;

EID: 74049100206     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107.
2. Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population-a viral marker study. Ann Acad Med Singapore. 1980;9(2):144-8.
3. Bagheri-Lankarani K, Saberi-Firoozi M, Nabipoor l. Reassessment of the role of hepatitis B and C viruses in postnecrotic cirrhosis and chronic hepatitis in southern Iran. Iran J Med Sci. 1999;24:119-21.
4. Shamszad M, Farzadegan H. Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. J Iran Med Council. 1982;8:238.
5. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J. 2005;26(6):974-7.
6. Lai MM. The molecular biology of hepatitis delta virus. Annu Rev Biochem. 1995;64:259-86.
7. Farci P. Delta hepatitis: an update. J Hepatol. 2003;39 Suppl 1:S212-9.
8. Rezvan H, Forouzandeh B, Taroyan S, Fadaiee S, Azordegan F. A study on delta virus infection and its clinical impact in Iran. Infection. 1990;18(1):26-8.
9. Malekzadeh R, Borhanmanesh F. Prevalence of HDV in asymptomatic healthy carrier of HBV in Iran. Iran J Med Sci. 1989;14(2):33-8.
10. Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 1990;8 Suppl:S18-20; discussion S1-3.
11. Incidence of acute hepatitis B-United States, 1990-2002. MMWR Morb Mortal Wkly Rep. 2004;52(51-52):1252-4.
12. Alavian S. We have more data regarding epidemiology of hepatitis D in Iran but there are defects to be filled yet! Hepat Mon. 2008;8(4):245-7.
13. Karimi A, Amini S, Amirkhani A. [Investigation and Comparison of hepatitis D prevalence in dialysis patients and the donors of HBsAg carrier]. Teb va Tazkieh. 2000;36:30-5.
14. Zahedi MJ. [Serologic Prevalence of Hepatitis D in HBsAg Positive Patients in Kerman, South of Iran, 2002-2003]. Kerman University of Medical Sciences and Health Services. Document No 81/55; 2003.
15. Amini S, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: a population based study. J Trop Med Hyg. 1993;96(5):277-87.
16. Alavian SM, Asari S, Manzoori-Joybari H, et al. [Frequency and Risk Factors of Hepatitis D Virus in Hepatitis B Patients]. Govaresh. 2005;10(1):21-6.
17. Taghavi S, Sedighi S, Mehrabani D, Khademolhosseini F. Hepatitis D in chronic active hepatitis B: prevalence, liver enzymes and histopathology-an epidemiological study in Shiraz, southern Iran, 2003-2004. Hepat Mon. 2008;4(8):248-51.
18. Roshandel G, Semnani S, Abdolahi N, et al. Prevalence of hepatitis D virus infection in HBsAg positive subjects in Iran. Pak J Biol Sci. 2007;10(10):1751-4.
19. Torabi SE, Ebrahimpoor S, Maljaei SH, Naghili B. [Seroepidemiological studies of hepatitis Delta (HDV) in HBsAg positive individuals in Tabriz]. Urmia Med J. 2003;13(4):290-7.
20. Alavian S. Ministry of Health in Iran is serious about controlling hepatitis B. Hepat Mon. 2007;7(1):3-5.
21. Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet. 1982;2(8305):945-7.
22. Alavian SM, Alavian SH. Hepatitis D virus infection; Iran, Middle East and Central Asia. Hepat Mon. 2005;5(4):137-43.
23. Mumtaz K, Hamid SS, Adil S, et al. Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. J Gastroenterol Hepatol. 2005;20(10):1503-7.
24. Hassanjani Roshan MR, Beigi AA, Soleimani MJ. [Prevalence of anti-HDV in chronic carrier of HBV in Babol]. Babol Med J. 2002;6(21):50-4.
25. Alavian SM, Mostajabi P, Malekzadeh R, et al. [Evaluation of Hepatitis B transmission risk Factors in Tehran blood donors]. Govaresh. 2004;9(3):169-75.
26. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403- 6.
27. Hajiani E, Hashemi S, Masjedizadeh A. Seroepidemiology of hepatitis B virus Infection in Khuzestan province, southwest of Iran. Hepat Mon. 2009;9(1):34-8.
28. Sali S, Bashtar R, Alavian SM. Risk factors in chronic hepatitis B infection: a case-control study. Hepat Mon. 2005;5:109-15.
29. Nuchprayoon T, Chumnijarakij T. Risk factors for hepatitis B carrier status among blood donors of the National Blood Center, Thai Red Cross Society. Southeast Asian J Trop Med Public Health. 1992;23(2):246-53.
30. Zali MR, Mohammad K, Noorbala AA, Noorimayer B, Shahraz S. Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J. 2005;11(1-2):62-7.